Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng

Natural products have served as structural resources in the history of drug discovery for cancer therapy. Among these natural products, Korean Panax ginseng serves as a potential anti-cancer medicinal plant. To determine the anti-cancer activities of Korean P. ginseng active compounds, we performed pharmacophore-based virtual screening and molecular docking studies on EGFR (epidermal growth factor receptor) tyrosine kinase domain. The EGFR family tyrosine kinase receptor is a cell surface receptor that regulates diverse biological processes including cell proliferation, differentiation, survival, and apoptosis. Over expression of EGFR tyrosine kinase domain associated with the development and progression of numerous human cancers. In our study, we developed the best pharmacophore model (Hypo1) using a diverse training set and validated by Fischer's randomization, a test set, and a decoy set. The best validated model was employed in the virtual screening of P. ginseng compound database. Further, chosen molecules were evaluated by applying ADMET screening and molecular docking studies. Finally, 14 compounds were obtained based on binding affinity scores and interactions with protein active site residues. These final lead compounds from P. ginseng can be used in the designing of new EGFR tyrosine kinase inhibitors.

[1]  J. Dearden In silico prediction of aqueous solubility , 2006, Expert opinion on drug discovery.

[2]  Yunwei Wang,et al.  American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR , 2011, BMC complementary and alternative medicine.

[3]  A.K. Gupta,et al.  Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors , 2011, SAR and QSAR in environmental research.

[4]  Philippe Vayer,et al.  Toward in silico structure-based ADMET prediction in drug discovery. , 2012, Drug discovery today.

[5]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[6]  R. Yarden,et al.  Mechanisms of EGF receptor regulation in breast cancer cells , 2004, Breast Cancer Research and Treatment.

[7]  Deok-Chun Yang,et al.  Molecular docking studies of anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides from Panax ginseng , 2012, Journal of enzyme inhibition and medicinal chemistry.

[8]  Peter Gwynne,et al.  Drug Discovery: 5 , 2002 .

[9]  M. Karplus,et al.  Simulation of activation free energies in molecular systems , 1996 .

[10]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[11]  Deok-Chun Yang,et al.  Insilico Analysis for Expressed Sequence Tags from Embryogenic Callus and Flower Buds of Panax ginseng C. A. Meyer , 2011 .

[12]  Kwang-tae Choi,et al.  Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer , 2008, Acta Pharmacologica Sinica.

[13]  Gershteĭn Es,et al.  [Expression of epidermal growth factor receptors and their ligands in malignant tumors of the breast]. , 1996, Vestnik Rossiiskoi akademii meditsinskikh nauk.

[14]  Ramadevi Sanam,et al.  Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. , 2008, Journal of medicinal chemistry.

[15]  R. Mehta,et al.  Cancer Chemoprevention by Natural Products: How Far Have We Come? , 2010, Pharmaceutical Research.

[16]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[17]  G. Carter,et al.  Natural products and Pharma 2011: strategic changes spur new opportunities. , 2011, Natural product reports.

[18]  A. Ben Wagner,et al.  SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..

[19]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[20]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[21]  Paul N. Mortenson,et al.  Diverse, high-quality test set for the validation of protein-ligand docking performance. , 2007, Journal of medicinal chemistry.

[22]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[23]  T K Yun,et al.  Brief introduction of Panax ginseng C.A. Meyer. , 2001, Journal of Korean medical science.

[24]  D. Rhee,et al.  Biological Activities and Chemistry of Saponins from Panax ginseng C. A. Meyer , 2005, Phytochemistry Reviews.

[25]  Yun Tang,et al.  Chemical function-based pharmacophore generation of selective κ-opioid receptor agonists by catalyst and phase , 2009, Journal of molecular modeling.

[26]  Tingjun Hou,et al.  3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment , 2001, J. Chem. Inf. Comput. Sci..

[27]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[28]  T. Fojo,et al.  Epidermal Growth Factor Receptor Inhibitors: A Moving Target? , 2005, Clinical Cancer Research.

[29]  Chieh-fu Chen,et al.  Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium , 2008, Acta Pharmacologica Sinica.

[30]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[31]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[32]  D. Davies,et al.  Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. , 1994, Biochemical pharmacology.

[33]  Yi-Ping Phoebe Chen,et al.  Structure-based drug design to augment hit discovery. , 2011, Drug discovery today.

[34]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[35]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[36]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[37]  P. Harari,et al.  Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. , 2002, Seminars in radiation oncology.

[38]  Lars P Christensen,et al.  Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. , 2009, Advances in food and nutrition research.

[39]  Chien-Yu Chen,et al.  Insights into designing the dual-targeted HER2/HSP90 inhibitors. , 2010, Journal of molecular graphics & modelling.

[40]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[41]  C. G. Mohan,et al.  Computer-assisted methods in chemical toxicity prediction. , 2007, Mini reviews in medicinal chemistry.

[42]  Diana Nguyen,et al.  Epidermal growth factor receptor expression in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  O. Petrini,et al.  The Standardised G115® Panax ginseng C.A. Meyer Extract , 2005 .

[44]  G. Giaccone,et al.  Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. , 2003, The oncologist.

[45]  Nam Doo Kim,et al.  Pharmacophore-based virtual screening: a review of recent applications , 2010, Expert opinion on drug discovery.

[46]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[47]  Stefano Forli,et al.  Virtual screening with AutoDock: theory and practice , 2010, Expert opinion on drug discovery.

[48]  Om Silakari,et al.  A Three Dimensional Pharmacophore Modeling for KDR and Tie‐2 Receptor Tyrosine Kinase Inhibitors and Virtual Screening for New Multikinase Inhibitors , 2009 .

[49]  K. Leung,et al.  Pharmacology of ginsenosides: a literature review , 2010, Chinese medicine.

[50]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[51]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[52]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[53]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[54]  R. Saxena,et al.  ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective , 2012, Medicinal research reviews.

[55]  Muhammad Muddassar,et al.  In silico QSAR studies of anilinoquinolines as EGFR inhibitors , 2010, Journal of molecular modeling.

[56]  Edzard Ernst,et al.  Panax ginseng: An Overview of the Clinical Evidence , 2010 .

[57]  David W. Fry,et al.  Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors , 1994 .

[58]  Francesco Scaglione,et al.  The Standardised G115: A Review of its Properties and Usage : A Review of its Properties and Usagepanax ginseng: A Review of its Properties and Usage C.a. Meyer Extract: A Review of its Properties and Usage , 2005 .

[59]  T. Ganesan,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2004, Clinical biochemistry.

[60]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.